相关临床试验
1167
661 进行中
药物批准
23
批准总数
监管机构
2
监管机构数
成立时间
N/A
尚未招募
6
0.5%
No Longer Available
5
0.4%
终止
84
7.2%
招募中
23
2.0%
Approved For Marketing
2
0.2%
撤回
14
1.2%
Available
2
0.2%
进行中（未招募）
655
56.1%
Unknown
2
0.2%
已完成
374
32.0%
- Remedy Plan Therapeutics has initiated enrollment in Cohort 2 of its Phase 1 dose escalation trial of RPT1G in relapsed/refractory AML and higher-risk MDS. - The FDA has accepted an Investigational New Drug application for RPT1G in solid tumors, expanding the program beyond hematologic malignancies. - Cohort 1 patients completed the first full 28-day treatment cycle, which the company says marks the first sustained therapeutic NAMPT inhibition without limiting toxicity in cancer patients. - The company closed a Series A extension of approximately $30 million and appointed Oleg Zernovak, M.D. as Vice President, Clinical Development.
- A new philanthropic fund, INBI Core, aims to raise $500 million over ten years to commercialize life science technologies from all Israeli universities. - The initiative is led by Samuel Moed, former head of Corporate Strategy at Bristol Myers Squibb, with Dr. Anat Cohen-Dayag serving as CEO. - Fifteen Israeli academic institutions and major healthcare organizations, including Maccabi, Clalit, and six hospitals, have joined as partners. - INBI will bridge the gap between academia and industry by setting up startups and granting commercialization licenses to pharma companies.
- Jennifer Taubert is retiring as Executive Vice President and Worldwide Chairman of Innovative Medicine at Johnson & Johnson after more than 21 years with the company. - Under Taubert's leadership, the Innovative Medicine business grew to more than $60 billion in annual revenue across oncology, immunology, neuroscience, and cardiovascular disease. - Tom Cavanaugh, currently Company Group Chairman for North America, will succeed Taubert effective September 1, 2026, and join the Executive Committee. - Cavanaugh brings nearly three decades of biopharmaceutical experience, including senior roles at J&J since 2017 and nearly 15 years at Celgene prior.
- Halia Therapeutics announced final Phase 2 results for ofirnoflast (HT-6184) showing 67% hematological improvement rate in 30 evaluable patients with lower-risk myelodysplastic syndrome. - The first-in-class NEK7 inhibitor demonstrated 55% transfusion independence for at least 8 weeks among transfusion-dependent patients, with median duration of 28.5 weeks. - The trial reported no treatment-related serious adverse events, with treatment-related adverse events occurring in only 27% of patients. - The company appointed Han Myint, MD, FACP, as Chief Medical Officer to lead clinical development as ofirnoflast advances toward pivotal trials.
- Slate Medicines raised $130 million in Series A funding to advance SLTE-1009, an anti-PACAP monoclonal antibody for migraine prevention acquired from DartsBio Pharmaceuticals. - PACAP represents a distinct clinically validated target compared to CGRP, potentially offering benefits for patients inadequately treated by current migraine therapies. - The therapy incorporates half-life extension technology enabling convenient at-home subcutaneous dosing, positioning it as a differentiated treatment option. - The company is led by experienced executives including CEO Gregory Oakes and CMO Roger Cady, with backing from prominent investors RA Capital, Forbion, and Foresite Capital.
- Bristol Myers Squibb announced FDA acceptance of its New Drug Application for iberdomide, a novel CELMoD agent, combined with daratumumab and dexamethasone for relapsed or refractory multiple myeloma. - The FDA granted Breakthrough Therapy Designation and Priority Review with a PDUFA date of August 17, 2026, positioning iberdomide as a potential first-in-class CELMoD therapy. - The filing tests FDA's new regulatory flexibility by relying on minimal residual disease (MRD) negativity data from the Phase 3 EXCALIBER-RRMM trial, with progression-free survival data still immature. - Iberdomide represents a potential successor to the now off-patent Revlimid, utilizing targeted protein degradation to modulate Ikaros and Aiolos proteins in multiple myeloma treatment.
- The fourth quarter of 2025 witnessed an unprecedented surge in ANDA patent litigation cases, with over 80 new lawsuits filed as generic manufacturers challenged patents protecting major pharmaceutical products. - High-value drug patents faced multiple challenges, including Bayer's Kerendia (finerenone) targeted by at least 10 generic companies and AbbVie's Qulipta (atogepant) facing litigation from multiple manufacturers. - Settlement activity remained robust with over 50 cases resolved, often resulting in injunctions preventing generic entry until patent expiration while allowing FDA approval processes to continue.
- A decade-long multicenter trial of 247 patients demonstrated that five-day azacitidine significantly improved event-free survival and overall survival compared to three-day azacitidine or decitabine regimens in lower-risk myelodysplastic syndrome. - The five-day azacitidine regimen achieved overall response rates of 48% in transfusion-dependent patients and 70% in transfusion-independent patients while maintaining a favorable safety profile without increased toxicity. - These findings establish five-day azacitidine as the optimal shorter-duration hypomethylating agent regimen for lower-risk MDS, offering improved outcomes with reduced side effects compared to traditional seven-day protocols.
- Bristol Myers Squibb's Breyanzi received FDA approval for treating relapsed or refractory marginal zone lymphoma, becoming the first cell therapy available for this rare lymphatic tumor. - The approval represents Breyanzi's fifth indication and addresses a significant unmet need in marginal zone lymphoma, which accounts for approximately 7% of all B-cell non-Hodgkin lymphoma cases. - Breyanzi has demonstrated strong commercial performance with $747 million in sales in 2024 and $966 million over the first nine months of 2025.
- Bristol-Myers Squibb has exercised its option on Prothena's PRX005, a tau-targeting antibody for Alzheimer's disease, in a deal potentially worth $2.2 billion with $55 million upfront. - PRX005 specifically targets the microtubule-binding region of tau protein, which correlates more closely with dementia stages than other tau regions according to cerebrospinal fluid analysis. - The antibody completed phase 1 single ascending dose studies showing safety and effective central nervous system penetration, with multiple ascending dose results expected by year-end. - This move makes PRX005 the centerpiece of BMS's neuroscience pipeline, marking the company's return to Alzheimer's drug development after previous exits from the field.
